Executive Summary

A novel class of agents for the treatment of retinal disease demonstrating:

• Improved retinal anatomy and function.
• Improved visual acuity.
• No evidence of sustained increase in IOP or cataractogenisis.
• Significant inhibition in rate of GA lesion spread.
•  No evidence of refractility.
• Patents have been granted in over 30 countries for its use in Dry-AMD and GA.